Total cholesterol was measured by the cholesterol oxidase method (Roche COBAS Fara analyzer; Roche Diagnostics), as previously described [5] (link). Ideal total cholesterol was defined as an untreated total cholesterol <200 mg/dL; intermediate total cholesterol defined by a level of 200 to 239 mg/dL or if treated with anti-hyperlipidemic medications to goal (<200 mg/dL); and poor was defined by a level of ≥240 mg/dL.
Cobas fara analyzer
Manufactured by Roche
Sourced in United States
The Roche COBAS Fara analyzer is a laboratory instrument designed for the automated analysis of clinical samples. It is capable of performing a variety of clinical chemistry and immunochemistry tests. The COBAS Fara analyzer is intended to aid healthcare professionals in the diagnosis, monitoring, and treatment of various medical conditions.
Automatically generated - may contain errors
Lab products found in correlation
5 protocols using cobas fara analyzer
1
Cholesterol Measurement Protocol
2
Lp(a) Measurement Across Cohorts
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Serum Lp(a)-C was measured in both EST and JHS via density gradient ultracentrifugation (Vertical Auto Profile [VAP], Atherotech).
Lp(a) was measured in JHS using a Diasorin nephelometric assay on a Roche Cobas FARA analyzer (Roche Diagnostics Corporation, Indianapolis, IN, USA), which measures Lp(a) mass by immunoprecipitin analysis using the SPQTM Antibody Reagent System of DiaSorin (DiaSorin Inc., Stillwater, MN 55082-0285). Turbidity produced by the antigen–antibody complexes was measured using the Roche Modular P Chemistry Analyzer. In FIN, Lp(a) was measured from serum stored at –70 °C using a commercially available latex immunoassay on an Architect c8000 system (Quantia Lp(a), Abbott Diagnostics).
Lp(a)-C and Lp(a) were inverse-rank normalized separately by cohort for analysis.
Lp(a) was measured in JHS using a Diasorin nephelometric assay on a Roche Cobas FARA analyzer (Roche Diagnostics Corporation, Indianapolis, IN, USA), which measures Lp(a) mass by immunoprecipitin analysis using the SPQTM Antibody Reagent System of DiaSorin (DiaSorin Inc., Stillwater, MN 55082-0285). Turbidity produced by the antigen–antibody complexes was measured using the Roche Modular P Chemistry Analyzer. In FIN, Lp(a) was measured from serum stored at –70 °C using a commercially available latex immunoassay on an Architect c8000 system (Quantia Lp(a), Abbott Diagnostics).
Lp(a)-C and Lp(a) were inverse-rank normalized separately by cohort for analysis.
3
Measuring Total Cholesterol Levels
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Total cholesterol was measured by the cholesterol oxidase method (Roche COBAS Fara analyzer; Roche Diagnostics), as previously described [19] (link). Ideal total cholesterol was defined as an untreated total cholesterol <200 mg/dL; intermediate total cholesterol defined by a level of 200 to 239 mg/dL or if treated with anti-hyperlipidemic medications to goal (<200 mg/dL); and poor was defined by a level of ≥240 mg/dL [6] (link).
4
Measuring Ideal Total Cholesterol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Total cholesterol was measured by the cholesterol oxidase method (Roche COBAS Fara analyzer; Roche Diagnostics), as previously described [3 (link)]. Ideal total cholesterol was defined as an untreated total cholesterol <200 mg/dL; intermediate total cholesterol defined by a level of 200–239 mg/dL or if treated to goal (<200 mg/dL); and poor was defined by a level of ≥240 mg/dL [1 (link)].
5
Lp(a) Levels and Genetics in African Americans
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
This study included 1106 AA male and 1789 AA female participants with measured Lp(a) levels and available genome-wide genotype data from the JHS, a longitudinal, population-based cohort from Jackson, Mississippi, USA. 12 The design, recruitment and initial characterization of this study was described in detail elsewhere. 13 Serum Lp(a) levels (mg dl -1 ) were measured using a Diasorin nephelometric assay on a Roche Cobas FARA analyzer (Roche Diagnostics Corporation, Indianapolis, IN, USA). 14 Fasting LDL, high-density lipoprotein (HDL), triglyceride (TG) and total cholesterol (TC) were measured as described previously. 15 For each individual treated with lipid-lowering therapies, the observed lipid value was multiplied by a correction factor (1.352 for LDL, 0.949 for HDL, 1.210 for TG and 1.271 for TC). 16 The study protocol was approved by the University of Mississippi Medical Center Institutional Review Board, and written informed consent was obtained from all JHS participants. Descriptive characteristics of the JHS participants in this study were summarized in Table 1.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!